ESTRO 2024 - Abstract Book
S1580
Clinical - Lung
ESTRO 2024
(HR=0.16, 95% CI 0.08-0.30; p<0.001). At the optimal cut-off values for NLR and SII, the biomarkers could significantly and moderately distinguish between patients with or without response (AUC = 0.71, 95% confidence interval (CI) = 0.59 – 0.82; p = 0.003), with a sensitivity of 63.2% and a specificity of 80.0% for NLR and (AUC = 0.71, 95% confidence interval (CI) = 0.58 – 0.83; p = 0.003), with a sensitivity of 63.2% and a specificity of 80.0% for SII.
Conclusion:
The SII and NLR are promising prognostic predictors for patients with metastatic NSCLC patients. Patients treated with immunotherapy had better response from patients treated with chemotherapy after GKRS.
Keywords: Brain metastases, SII, NLR
70
Digital Poster
Developing imaging biomarkers for the incidence of RP in patients with NSCLC who have underlying IPF
Hakyoung Kim 1 , Jeongeun Hwang 2 , Dae Sik Yang 1 , Young Bum Kim 1
1 Korea University College of Medicine, Departments of Radiation Oncology, Seoul, Korea, Republic of. 2 Soonchunhyang University, Department of Medical IT Engineering, Asan, Chungcheongnam-do, Korea, Republic of
Purpose/Objective:
Idiopathic pulmonary fibrosis (IPF) has the potential to cause fatal pulmonary toxicity after radiotherapy and can increase the morbidity and mortality of non-small cell lung cancer (NSCLC) patients. In this context, we aimed to develop imaging complexity biomarkers to predict the incidence of severe pulmonary toxicity in patients with NSCLC who have underlying IPF and are treated with radiotherapy.
Material/Methods:
We retrospectively reviewed the medical records of 257 patients with NSCLC who underwent thoracic X-ray radiotherapy at the Korea University Guro Hospital between March 2018 and December 2022. All diagnoses of the underlying pulmonary diseases were confirmed by experienced pulmonologists (J.H.C.). Among them, patients with no underlying pulmonary disease other than IPF, such as COPD, and those lacking pulmonary function tests were excluded; 19 patients with underlying IPF were included in this study. The planned total dose and fractions differed according to the location of lung lesions. Based on the institutional protocol, stereotactic ablative radiation therapy (SABR) with a total dose of 60 Gy in four fractions was administered to NSCLC patients with small- sized (≤ 4 cm) and peripherally located tumors. For patients who received intensity modulated radiation therapy (IMRT), two different dose-fractionation schedules were planned to deliver 60 Gy in 20
Made with FlippingBook - Online Brochure Maker